Sydney, Australia, 20 September 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, is pleased to announce the Japan Patent Office (JPO) has Granted a second patent for wholly owned RECCE® antibiotics, including lead compound RECCE® 327, furthering marketing/manufacturing monopolies and expanding clinical indications.
This second patent family, titled ‘Copolymer for use in a method of treatment of a parenteral infection’, contains 13 claims and relates to methods of manufacture, administration and application to treat a broad range of common human infections, providing Recce intellectual property protection to November 2035.
Japan is the second largest pharmaceutical market in the world1 and reaffirms RECCE® antibiotics capability against Gram-positive and Gram-negative bacteria, including their superbug forms, with particular claim to efficacy against: Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp. The listed bacteria can be life-threatening if contracted.
Recce Pharmaceuticals Chairman Dr John Prendergast said: “We are very pleased to continue the expansion of Recce’s Worldwide Patent portfolio. The strength of our patent coverage is yet another step in the commercialization of RECCE antibiotics across multiple geographic regions.”
About Recce Pharmaceuticals
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S.aureus bacteria – including their superbug forms. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE®; technologies targeting synergistic, unmet medical needs.
Connect with us via Twitter @ReccePharma and LinkedIn
For further information please visit www.recce.com.au or contact:
Distributed for and on behalf Recce Pharmaceuticals by Instinctif Partners.
For more information please contact: Recce@instinctif.com
Sue CharlesManaging Partner